ArticleCancers2022

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells.

Caterina Riillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.